PathoVax is a Johns Hopkins–born startup developing RGVax, a vaccine designed to protect against all cancer-causing forms of HPV. The company raised $2.75 million in new equity funding. The round was led by United Heath Investments, with participation from private investors. United Heath Investments is a life-science investment group led by Dr. Alan Zhu, who directs the Baltimore-based Chinese Association for Medical Professionals, which counts 800 physicians and seeks to strengthen ties between U.S. and Chinese medical communities. Cofounder Joshua Wang announced the raise, and the article notes the company has grown its team. Existing HPV vaccines protect against some strains; PathoVax aims to broaden protection to all cancer-causing types.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2018